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Abstract
Background: General practitioners (GPs) have an increasing role in referring
patients with putative mutation in BRCA1/2 genes for genetics consultation and
for long‐term follow‐up of mutation carriers.
Methods: We compared the expectations of the GPs’ role according to BRCA1/2
mutation carriers and to GPs themselves.
Results: Overall, 38% (58/152) of eligible GPs and 70% (176/252) of eligible
patients were surveyed. Although 81% of GPs collected the family history, only
24% considered that they know criteria indicating genetics consultation and 39%
sufficient knowledge of BRCA1/2 guidelines to answer patients’ questions.
Twelve% of GPs were aware of the French national guidelines. Among unsatis-
fied patients, 40% felt that their GP was able to answer (moderately, sufficiently,
or completely) specific questions about BRCA1/2 care as compared with 81% in
satisfied patients. Only 33% of GPs reported being informed directly by the
geneticist about the patients’ results. GPs’ main expectations for their role in
BRCA1/2 carrier care were psychological support and informing relatives about
screening (72% and 71%, respectively), which contrasts with the perceptions of
patients, who mainly requested medical advice for BRCA1/2‐related care (51%).
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Conclusion: There is an important need for GP training and enhancing interac-
tions between GPs and geneticists to improve the GP's role in BRCA1/2 screening
and management.
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1 | INTRODUCTION
Deleterious mutations of BRCA1 and BRCA2, the two major
genes involved in hereditary breast and ovarian cancer syn-
drome (Cleton‐Jansen et al., 1995; Goldgar et al., 1994),
are found in 1 per 300–500 women in the Caucasian gen-
eral population (Anglian Breast Cancer (ABC) Study
Group, 2000; Peto et al., 1999). The high risk of breast and
ovarian cancer (Antoniou et al., 2003; Chen & Parmigiani,
2007; Giannakeas & Narod, 2018) in this population
requires knowledge of personal and familial criteria for
genetic counseling as well as specific long‐term follow‐up
for screening and prevention strategies (Daly et al., 2017).
The expansion of genetic testing indications and the use
of targeted therapies (such as PARP inhibitors) (Konecny
& Kristeleit, 2016), in addition to conventional screening,
has increased the number of individuals identified as carry-
ing BRCA1/2 mutations. Hence, the role of general practi-
tioners (GPs) in identifying an indication for genetic testing
and long‐term follow‐up of patients is crucial. Still, the
involvement of GPs in the BRCA1/2 care process remains
mostly unexplored.
The aim of this study was to evaluate the role of GPs in
the care of BRCA1/2 mutation carriers and to compare the
expectations of BRCA1/2 mutation carriers for the GP role
with those of GPs themselves.
2 | MATERIAL AND METHODS
2.1 | Design of the study
Our study was a multicentric, descriptive, prospective, clin-
ical, double unpaired cohort study performed from July to
September 2017. It was a descriptive cross‐sectional obser-
vational, noninterventional research. The study protocol
was reported by the Clinical Investigation Center of
University Hospital of Montpellier to ClinicalTrials.gov
(Identifier: NCT03211611) on July 7, 2017.
2.2 | Ethics
This study involved the collection of epidemiological, clini-
cal, and genetic data from the medical files of patients and
survey completion by email, telephone/fax, or mail. There
was no medical intervention or change in patient health
care. The study's protocol was approved by the ethics com-
mittee of Montpellier University Hospital and was declared
to the National Commission for Computing and Liberties
(CNIL, Supporting Information Appendix S2). All patients
gave their written informed consent to participate. Anon-
ymity was guaranteed for both GPs and patients by ran-
domly assigning an anonymous identification number for
collection of survey data.
2.3 | Patient enrollment and assessment
The flow of patients is in Figure 1. The recruitment of
BRCA1/2 mutated carriers was multicentric, involving can-
cer genetics units attached to the University Hospital of
Montpellier (Centre Hospitalier Universitaire, CHU;
Arnaud de Villeneuve Hospital, Montpellier Cancer Insti-
tute, Béziers Hospital, Perpignan Hospital), the Hartmann
Oncology Center, and the Institut Hospitalier Franco‐Bri-
tannique in Levallois‐Perret. A subpopulation of BRCA1/2
mutation carriers from the patient association BRCA
France was enrolled via the association “BRCA France” on
a voluntary basis.
We included women older than 18 years with geneti-
cally identified BRCA1/2 germline mutation, with or with-
out a cancer history, who were registered under the
national social security scheme. Patients under guardianship
or trusteeship, who were unable to consent for research or
those protected by law, were not included. Patients were
called by phone to inform them about the study's purpose
and confidentiality of their responses. They were informed
that the cancer genetics department of the CHU of Mont-
pellier managed the study and that the BRCA France
patient association was participating in patient recruitment.
An information and consent statement was sent by mail
or email (Supporting Information Appendix S1). Once they
signed and returned the consent form, the included patients
completed a questionnaire containing 17 questions (closed
dichotomous questions, multiple‐choice closed questions,
conditional question, and questions with rating scales). This
survey was organized in a multistep process, exploring
demographic characteristics (age, distance from their living
place to the GP's office or the cancer genetics center) and
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assessing medical management before the initial cancer
genetics consultation and while awaiting the results. Then,
the announcement of the results and the preventive treat-
ment choices were explored. Finally, the medical follow‐up
and the patient's satisfaction with the involvement of their
GP in their specific follow‐up care related to BRCA1/2
mutation carriage (primary endpoint) were assessed. This
questionnaire is provided in Supporting Information
Appendix S3. Patients could use their anonymous identifi-
cation number to complete this questionnaire by phone,
mail, or email (using a Google Form questionnaire). In the
absence of an answer, patients were phoned or emailed
twice.
The primary endpoint for patient assessment was rate of
patients satisfied with the role their GP plays in their care
related to BRCA1/2 mutation carriage. Secondary endpoints
were the patient's assessment of the GP's most important
role in BRCA1/2‐related care and patients’ expectations of
the GP's role.
2.4 | GP enrollment and assessment
The flow of GPs in the study is in Figure 2. The Medifirst
and DxCare secure medical software used in routine prac-
tice in the cancer genetics department of Montpellier
University Hospital lists patients carrying mutations in
BRCA1 or BRCA2 and identifies their referenced GPs,
respectively. GPs were contacted by phone to explain the
study and the method of anonymization. We included GPs
who agreed to participate during this first telephone
contact. We reminded them of their patient's name when
they asked for it.
General practitioners self‐assessment of BRCA1/2 carri-
ers’ care was examined by a survey with 19 closed ques-
tions (Supporting Information Appendix S4). The survey
items covered the demographic characteristics of GPs (sex,
age, and place of practice) and a self‐assessment of the
GPs’ knowledge of BRCA1/2 mutations predisposing to
cancer and their practices. This questionnaire was
FIGURE 1 Flow of patients in the
study
FIGURE 2 Flow of general practitioners (GPs) in the study
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anonymized with the anonymous identification number pre-
viously communicated by email or by fax to GPs. GPs
could answer the questionnaire by using Google Form or
during a phone call or send the completed form by fax. In
the absence of an answer, GPs were phoned or emailed
twice. Any questionnaire even incomplete was considered.
The primary endpoint of the GP assessment was the rate
of GPs considering that they had enough knowledge for
appropriate care of patients with BRCA1/2 mutation. This
self‐assessment was characterized by three items:
 The self‐estimated level of systematic research for family
history of cancer from the history taking with patients,
 The self‐perceived knowledge of the criteria required to
refer the patient for cancer genetics consultation,
 The self‐evaluated ability to answer questions from
patients about BRCA1/2 mutations.
Secondary endpoints were the rate of GPs seeking can-
cer genetics training and that of GPs being informed about
a medical report from the oncogeneticist about their
patient's BRCA1/2 mutation status.
2.5 | Statistical analysis
Data entry and statistical analysis involved using Excel and
BiostaTGV (Institut Pierre Louis d'Epidémiologie et de
Santé Publique UMR S1136, https://biostatgv.sentiweb.fr).
Data are presented as number (%; range) or mean ± SD.
Results were analyzed by sex for GPs and the satisfaction
criterion for patients by using the chi‐square or Fisher test.
p < 0.05 was considered statistically significant.
3 | RESULTS
3.1 | Patient assessment
Overall, 424 patients from the Montpellier University Hospi-
tal oncogenetics department and 30 from the Hartmann
Oncology Center were eligible; 46 additional patients were
enrolled voluntarily via the BRCA France website. Among
the 500 patients, 252 (50.4%) were telephoned or emailed:
16 (6.3%) agreed to answer by phone, 28 (11.1%) by mail,
and 204 (81%) by email. Only four patients (1.6%) refused to
participate, including one who was her own GP. Finally,
from July to September 2017, 176/252 (69.8%) question-
naires were returned: 16 patients answered by telephone, 15
by mail, and 145 by email. For the 176 respondents, the
mean age was 49.1 ± 13.68 years (range: 22–85); (Support-
ing Information Appendix Table S5); 101/175 (57.7%) had a
personal history of cancer related to BRCA1/2. Most lived
within 10 km of their GP's office (137/169, 81%), but the
distance to the genetics department was more variable. A
total of 46 (26.4%), 57 (32.8%), and 46 (26.4%) patients
lived in urban, semirural, and rural areas, respectively.
Overall, 132/175 (75.4%) women were satisfied with
their GP's role in their care (Table 1 and Supporting Infor-
mation). Geographical distance to the GP office and the
cancer genetic center did not affect the level of patient sat-
isfaction (no difference in distance between satisfied and
unsatisfied patients’ subgroups).
Before the genetics results disclosure, only 46/175
(26.3%) patients consulted their GP. Consultation with the
GP before the genetics consultation was more frequent for
satisfied than unsatisfied patients (32.5% vs. 7%,
p < 0.001). Satisfaction of patients was associated with the
reported clinical breast surveillance role performed by GPs
(19% 33/173, Table 1; p < 0.01). The ability of GPs to
answer questions was deemed significantly higher for satis-
fied than unsatisfied patients (p < 0.01). Additional infor-
mation was searched more often independently by
unsatisfied than satisfied patients (p < 0.01).
Only, 22/175 (12.5%) patients considered the psycho-
logical support of GPs necessary pending the genetics
results.
3.2 | GP assessment
From July to September 2017, 152 GPs were called and
120 agreed to participate and were included in the study;
58 (38.2%) answered the questionnaire.
The GPs were mostly older than 50 years (46/58,
79.3%) and 24/58 (41%) were women. A total of 30 (52%),
21 (36%), and 7 (12%) practiced in urban, semirural, and
rural areas, respectively (Supporting Information
Appendix Table S6). Overall, 47/58 (81%) GPs collected
the family history and only 14/58 (24%) considered they
had sufficient knowledge of the indication criteria for
genetics consultation (Table 2). Also, 28/46 (69.7%) con-
sidered that they were not able to answer patients’ ques-
tions about BRCA1/2 guidelines. Many GPs (24/58, 72.4%)
felt not included (24/58) or that they had a minor role (18/
58) in the care of their patients. GPs’ answers are detailed
in supplementary material.
After stratification by sex, female GPs were signifi-
cantly better acquainted with the criteria for referring
patients to cancer genetics departments (p = 0.04) and felt
more competent to answer patients’ questions (p = 0.03)
than male GPs (Table 2).
A total of 14/51 (27.5%) GPs were trained during their
initial training to care for patients with a BRCA1/2 muta-
tion (Supporting Information Appendix Table S6), in light
of most responding GPs being older than 50 years (79.3%).
Only 11.8% of the GPs attributed their knowledge on the
subject to the referral guidelines of the French national can-
cer institute (INCa).
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Overall, only 19/58 (32.8%) GPs reported receiving a
letter from the geneticist.
3.3 | Comparison between GP and patient
responses
We compared the overall results for several items of the
questionnaires between the study groups. Figure 3 com-
pares the actual role of GPs according to the 176 patients
and what the 58 GPs expected as their future role in care
of patients with BRCA1/2 mutations: Patients mainly
expected care of other pathologies other than BRAC1/2
mutations from their GPs, and GPs mainly expected they
would motivate relatives for screening and provide psycho-
logical support. Figure 4 compares the role of the GP
according to the 176 patients with the role of the GP
expected by the 43 unsatisfied patients: All patients
expected they would be followed by the specialist and
unsatisfied patients mainly expected advice about their
medical BRCA‐related care from their GP.
4 | DISCUSSION
We report a double cohort study that evaluated and com-
pared the perceptions of patients and GPs concerning GPs’
involvement in care of patients with BRCA1/2 mutation.
TABLE 1 Characteristics of patients with BRCA1/2 mutation by their satisfaction or not with the involvement of their GP in their specific
follow‐up care (n = 176)
Characteristics Answers
Unsatisfied
n = 43(%)
Satisfied
n = 132 (%)
Total
N pa
Personal history of cancer Yes 24 (55.8) 77 (58.3) 101 0.77
No 19 (44.2) 55 (41.7) 74
GP consultation before geneticist Yes 3 (7) 43 (32.5) 46 0.0009
No 40 (93) 89 (67.5) 129
Ability of GP to answer BRCA1/2‐specific questions from
patients
1‐Not at all 23 (60.5) 22 (18.2) 45 0.0001
2‐A little
3‐Moderately 11 (29) 40 (33) 51
4‐Sufficiently 4 (10.5) 59 (48.8) 63
5‐Completely
Personal research Yes 29 (67.4) 52 (39.7) 81 0.0016
No 14 (32.5) 79 (60.3) 93
GPs should provide psychological support before disclosure of
the results
1‐Totally disagree 35 (81.4) 95 (72) 130 0.26
2‐Somewhat
disagree
3‐Neither agree nor
disagree
4 (9.3) 19 (14.4) 23
4‐Rather agree 4 (9.3) 18 (13.6) 22
5‐Totally agree
Possibility to ask the geneticist about BRCA1/2 care and
follow‐up questions
Yes 33 (76.7) 114 (86.4) 147 0.09
No 9 (21) 16 (12.1) 25
Practitioner responsible for strategy option (breast screening or
surgery)
Oncogeneticist 35 (94.6) 74 (66.7) 109 0.0032
GP 2(5.4) 37 (33.3) 39
Practitioner responsible for breast surveillance GP 1 (2.3) 32 (24.4) 33 0.0016
Gynecologist 41 (97.7) 99 (75.6) 140
Oncologist
Oncogeneticist
Radiologist
No one
Notes. Any questionnaire answered, even incomplete was considered.
GP: general practitioner.
ap < 0.05 by chi‐square or Fisher exact test.
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This study revealed that GPs are poorly informed (both by
specialists and by patients) of the result of the genetic
BRCA1/2 analysis: In our study, only 32.8% of GPs
thought that they were notified of the genetics results for
their patient. Therefore, it is not surprising that many GPs
(72.4%) felt little involved in the BRCA1/2 care of their
patients. The inclusion of GPs in the BRCA1/2 care process
should be improved. Although a center effect could not be
ruled out, we believe that a better information and return
of the results of the genetics analysis to the GP are
required.
Potential bias of this study is the representativity of the
subset (38%) of the GPs answering the survey. However, it
is likely that GPs responding may be interested by the
question of BRCA1/2 care and that the insufficiency of
knowledges of guidelines may be underestimated.
Most GPs considered that they were not familiar with
the criteria for referring patients to cancer genetics consul-
tations (75.9%), which in a previous study was evaluated
as one of the main elements of GPs’ cancer genetics train-
ing (Houwink et al., 2012). Only 17.2% of our GPs
referred their patient with BRCA1/2 mutation to the onco-
genetics consultation, but most GPs looked for a family
history of cancer during the consultation (81%).
The increased involvement of women GPs in referring
patients with extreme risk of breast cancer and/or ovarian
cancer to oncogenetics consultation was previously
observed (Campbell et al., 2003). In addition, a European
study showed that female GPs had a more positive attitude
about prophylactic mastectomy than male GPs and that
knowledge of breast/ovarian cancer genetics was associated
with a more positive attitude about prophylactic mastec-
tomy (Den Heijer et al., 2013). Therefore, our sample
of GPs seems representative of others described in the
literature.
Our GPs’ self‐assessment was not controlled by a test
of their effective knowledge. The absence of knowledge of
the referral guidelines of the INCa is consistent with their
self‐reported lack of awareness about indications of genetic
tests and medical guidelines on BRCA1/2. A European
TABLE 2 Rate of knowledge of GPs for appropriate care of
patients with BRCA1/2 mutation by sex (n = 58)
Characteristics Total
Answer
(N)
Women
n = 24
N (%)
Men
n = 24 N
(%) pa
Family history of
cancer
systematically
referred by GP
58 Yes (47) 22 (91.7) 25 (73.5) 0.08
No (11) 2 (8.3) 9 (26.5)
Knowledge of
referral
guidelines in
cancer genetics
consultation
58 Yes (14) 9 (37.5) 5 (14.7) 0.04
No (44) 15 (62.5) 29 (85.3)
Ability of GP to
answer BRCA1/
2 management
and follow‐up
questions
46 Yes (18) 10 (58.8) 8 (27.6) 0.03
No (28) 7 (41.2) 21 (72.4)
ap < 0.05 by chi‐square test.
FIGURE 3 Comparison between the actual role of GPs in the BRCA1/2‐related care according to the patients (n = 176, in blue) and the
GPs (n = 58, in orange)
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study of cancer risk assessment, predictive testing, and
management by GPs and breast surgeons reported that
physicians of all evaluated countries tend to fail to take
into account the paternal side of the family when collecting
the family history (Nippert et al., 2014).
In France, recommendations for breast cancer screening
in the general population with estimated “moderate risk”
by mammography every 2 years between age 50 and
74 years frequently involve GPs. Therefore, GPs need the
necessary knowledge to distinguish breast cancer risk
levels and refer the patient to genetics counseling when
appropriate.
General practitioners are poorly trained in the manage-
ment of BRCA1/2‐associated cancer risk, both in terms of
initial training and continuing education. Only one‐third of
the GPs answered our questionnaire (38.2%). Most GPs
assessed were older than 50 years, which is consistent with
data from the atlas of French medical demography from
the “Ordre des médecins” and may explain the lack of ini-
tial training on BRCA1/2 management. The INCa guideli-
nes were considered the main source of knowledge for
only 11.8% of GPs. In a 2013 European survey, only 30%
of French GPs considered prophylactic mastectomy an
option for an unaffected female BRCA1/2 mutation carrier
(as compared with 27%, 85%, and 92% in Germany, the
Netherlands, and United Kingdom, respectively) (Den Hei-
jer et al., 2013).
There is a real need for training GPs in the care of such
patients, and most are interested in training (79.6%), which
agrees with previous European (Nippert et al., 2014), US
(Friedman, Cooper, Webb, Weinberg, & Plon, 2003; Fried-
man, Plon, Cooper, & Weinberg, 1997), Australian (Teng
& Spigelman, 2014), and South African (Van Wyk, Wes-
sels, Kromberg, & Krause, 2016) studies.
Most GPs (69.7%) consider that they do not have the
necessary knowledge to answer their patient's questions.
Therefore, their main expected role in caring for these
patients is limited to psychological support (72.4%) and to
motivate relatives to undergo screening (70.7%). However,
this finding does not agree with patients who want their
GPs to be involved in their surveillance protocol and their
care: Most unsatisfied patients (51.1%) gave priority to
advice regarding their care breast/ovarian care. Overall,
12.5% of patients considered the psychological support of
GPs necessary pending the results and, after diagnosis,
23.9% considered that the psychological support was one
of the GP's roles. This request of patients to see GPs
involved in cancer genetics care is consistent with a previ-
ous similar study (Miller et al., 2010).
Therefore, the expectation of patients carrying a
BRCA1/2 mutation must be met by including GPs more
efficiently in the BRCA1/2 care process and providing
specific training to GPs. Previous studies have shown the
effectiveness and ease of establishing training in oncoge-
netics (Houwink et al., 2014; Scheuner et al., 2014; Wat-
son et al., 2001) or rare genetic diseases (Carroll et al.,
2009; Paneque et al., 2016) for GPs.
With the increasing number of BRCA1/2 mutation carri-
ers identified in the general population and the need for a
long‐term follow‐up, GPs will have an increasing role in
FIGURE 4 Comparison between the role of GPs according to the overall population of patients (n = 176 patients, in blue) and the
unsatisfied patients subgroup (n = 43, in yellow)
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the care of such patients. This work points to the crucial
need to improve GPs’ medical training in the indication for
tests and BRCA1/2 care guidelines. It also reports a major
expectation of patient mutation carriers for a higher
involvement of GPs in their medical care.
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